Shifting drinking patterns and rising health concerns have hit earnings, compounded by US tariffs, the impact of buoyant interest rates on consumer spending and even elevated commodity prices. The ...

Shifting drinking patterns and rising health concerns have hit earnings, compounded by US tariffs. Read more at ...

After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is ...

Lilly moved first. In January 2024, it launched LillyDirect, linking patients with telehealth providers and home delivery for its diabetes and weight-management portfolio. Pfizer followed in August ...

Shifting drinking patterns and rising health concerns have hit earnings, compounded by US tariffs, the impact of buoyant ...

Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...

According to new survey data from Gallup, for the first time in years, there’s a significant drop in obesity rates. The percentage of obese Americans has apparently dropped from 39.9% in 2022 to 37% ...

Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...

JCPenney and Ashley Graham defy the Ozempic trend with a bold, size-inclusive campaign that celebrates curves and drives ...

‘We were sitting down for a drink, and a guy came up to us and asked if it was a bachelorette and what we were doing. He told ...

Federal layoffs and government shutdown concerns are compounding worker anxieties about employment stability across public ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and ...